Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma reported its Q1 FY26 results, with standalone net sales falling sharply to ₹17,292.88 lakhs from ₹24,440.61 lakhs in Q1 FY25, a decline of about 29%. Standalone profit before tax dropped to ₹1,819.74 lakhs from ₹2,910.26 lakhs, a fall of roughly 37%, and EPS came in at ₹3.59 versus ₹5.74 a year ago. On a consolidated basis, net profit was ₹1,491.06 lakhs (down nearly 49% YoY) including a share of profit from associates of ₹119.94 lakhs. The statutory auditor Singhi & Co. issued an unmodified conclusion on standalone results but a qualified conclusion on consolidated results, flagging that three US subsidiaries' financials were unaudited. The board also approved the appointment of new Internal, Cost and Secretarial auditors and set September 20, 2025 as the AGM date.
Sharp year-on-year drops in both revenue and profit may weigh on short-term investor sentiment, while the qualified auditor opinion on consolidated numbers—due to unaudited US subsidiaries—adds a governance caveat. The ongoing amalgamation with Dhanuka Laboratories and AGM on September 20 are near-term events to watch.